Premium
Can we face the challenge of expanding use of intravenous immunoglobulin in neurology?
Author(s) -
Elovaara I.,
Hietaharju A.
Publication year - 2010
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.2009.01317.x
Subject(s) - neurology , medicine , antibody , face (sociological concept) , intensive care medicine , pediatrics , immunology , psychiatry , sociology , social science
Elovaara I, Hietaharju A. Can we face the challenge of expanding use of intravenous immunoglobulin in neurology?
Acta Neurol Scand: 2010: 122: 309–315.
© 2010 The Authors Journal compilation © 2010 Blackwell Munksgaard. The use of high‐dose polyclonal intravenous immunoglobulin (IVIG) in the treatment of autoimmune neurological diseases has expanded over the last decade. Based on controlled clinical trials IVIG can be considered currently as the first‐line treatment in Guillain‐Barré syndrome, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy, and it may be used as a rescue therapy in worsening myasthenia gravis. IVIG is a second‐line therapy in dermatomyositis, stiff‐person syndrome and pregnancy‐associated or postpartum relapses of multiple sclerosis. Although the biological efficacy of IVIG is due to multiple effects on the immune system, many mechanisms are still unknown. The awareness of risks and complications of IVIG therapy has increased, but severe side effects are still considered rare. Due to increasing costs of this treatment, careful selection of patients who will benefit from IVIG is extremely important.